AlphAIalphai — Financial news for AI agents
SEC EDGARMAY 271 min read$ONC

Sanders Corazon (Corsee) D. sold $66K of ONC

Sanders Corazon (Corsee) D. sold 212 shares of BeOne Medicines Ltd. (ONC) at $309.59 on 2026-05-22.

Original reporting
SEC EDGAR · Sanders Corazon (Corsee) D.
Published May 27, 2026, 9:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 27, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ONC
Neutral
medium confidence
Mentioned
$ONC
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ONCNeutralLow
01

Why it matters

The disclosure may slightly increase perceived downside risk for ONC due to insider selling, but it lacks accompanying operational or clinical catalysts.

02

Market read

Traders may monitor for follow-on insider activity, but the event alone is unlikely to drive a sustained move.

03

What to watch

The article doesn’t state whether the director had other holdings, compensation-related sales, or whether additional insider transactions occurred around the same time.

Relevance 6/10Timing: Immediate (today’s SEC Form 4 filing) but likely not catalyst-grade for price discovery.

Background

This is an SEC Form 4 insider transaction disclosure for BeOne Medicines Ltd. (ONC), reported by a director.

Company-level read

Ticker impact

$ONCNeutralMedium confidence
Context

A director of BeOne Medicines (ONC) sold 212 shares in an open-market transaction for ~$65.6K, leaving 0 shares after the sale.

Expected impact

Likely limited immediate impact; any reaction would be short-lived unless followed by additional insider selling or fundamental news.

Evidence & confidence

The filing is specific to ONC but provides only a small, one-off sale with no stated corporate catalyst in the article.

Market effects

Sector

Minimal; single-insider sale without accompanying trial/regulatory updates offers little sector read-across.

Regional

None indicated; filing is US SEC disclosure for a foreign-listed issuer.

Global

None indicated beyond routine insider transaction reporting.

Counterpoint

What could challenge this read

The director may have diversified personal holdings; absence of a 10b5-1 plan doesn’t necessarily imply negative fundamentals.

Key entities

  • issuer
    BeOne Medicines Ltd.

    Subject of the Form 4 insider sale; director sold 212 shares for ~$65.6K and reported 0 shares after transaction.

  • director
    Sanders Corazon (Corsee) D.

    Reporting insider who executed the open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ONC insider trading history →

Related articles

SEP 1
$ONCHighAI 9/10

FDA Approval Marks A Turning Point For BeOne Medicines (ONC)

BeOne Medicines (ONC) announced FDA approval for TEVIMBRA in combination with ZIIHERA and chemotherapy for HER2-positive gastroesophageal adenocarcinoma. The approval is based on Phase 3 trial data showing a median survival of 26.4 months. The company reported Q2 2026 revenue of $1.7 billion, up 30% YoY, and raised full-year revenue guidance to $6.6B-$6.8B. However, a Phase 3 study for zanubrutinib-sonrotoclax combination did not meet its primary endpoint.

yahoo.com2 min
SEP 1
$ALCMedAI 8/10

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

President Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.

tradingview.com3 min
SEP 1
$ALCLow

Trump Expands Drug Pricing Agreements With 9 Drugmakers— RFK Jr. Says President Called ‘Every Hour’ to En

President Trump announced drug pricing agreements with nine pharmaceutical companies, including Alcon (ALC), BeOne (ONC), BridgeBio (BBIO), and Teva (TEVA). The deals require discounts on outpatient drugs for Medicaid and $19.6B in U.S. manufacturing investments. This expands the total to 26 companies, covering 90% of the U.S. market. The White House estimates $529B in savings over a decade.

benzinga.com2 min
AUG 31
$ONCHighAI 8/10

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer

BeOne Medicines reported positive Phase 3 trial results for ZIIHERA (zanidatamab) plus chemotherapy, with and without TEVIMBRA (tislelizumab), in HER2+ gastroesophageal cancer. The study met its primary endpoint, showing statistically significant overall survival benefits. The FDA recently approved these regimens for first-line treatment. BeOne has rights to ZIIHERA in Asia, Australia, and New Zealand.

leaderpost.com2 min